For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.
Perini GF, et al1; Roberts AW2; Czabotar PE, et al3
Antiapoptotic BCL-2 family members are often found to be variably upregulated in many types of human cancers, such as different subtypes of B-cell lymphoma and solid tumors, and are frequently correlated with decreased susceptibility to chemotherapeutics and increased radioresistance.1 Overexpression of BCL-2 proteins may be an independent indicator of poor prognosis in malignancies including B-cell lymphomas and some solid tumors.1
- Perini GF, et al. J Hematol Oncol. 2018;11(1):65.
- Roberts AW. Hematology Am Soc Hematol Educ Program. 2020;2020(1):1-9.
- Czabotar PE, et al. Nat Rev Mol Cell Biol. 2014;15(1):49-63.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.